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Abstract
Background: Intermittent preventive treatment of malaria in children (IPTc) is a highly efficacious method of malaria control
where malaria transmission is highly seasonal. However, no studies published to date have examined community
perceptions of IPTc.
Methods: A qualitative study was undertaken in parallel with a double-blind, placebo-controlled, randomized trial of IPTc
conducted in Mali and Burkina Faso in 2008–2009 to assess community perceptions of and recommendations for IPTc.
Caregivers and community health workers (CHWs) were purposively sampled. Seventy-two in-depth individual interviews
and 23 focus group discussions were conducted.
Findings: Widespread perceptions of health benefits for children led to enthusiasm for the trial and for IPTc specifically.
Trust in and respect for those providing the tablets and a sense of obligation to the community to participate in sanctioned
activities favoured initial adoption. IPTc fits in well with existing understandings of childhood illness. Participants did not
express concerns about the specific drugs used for IPTc or about providing tablets to children without symptoms of malaria.
There was no evidence that IPTc was perceived as a substitute for bed net usage, nor did it inhibit care seeking. Participants
recommended that distribution be ‘‘closer to the population’’, but expressed concern over caregivers’ ability to administer
tablets at home.
Conclusions: The trial context mediated perceptions of IPTc. Nonetheless, the results indicate that community perceptions
of IPTc in the settings studied were largely favourable and that the delivery strategy rather than the tablets themselves
presented the main areas of concern for caregivers and CHWs. The study identifies a number of key questions to consider in
planning an IPTc distribution strategy. Single-dose formulations could increase the success of IPTc implementation, as could
integration of IPTc within a package of activities, such as bed net distribution and free curative care, for which demand is
already high.
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Introduction
In the Sahel and sub-Sahelian regions of Africa, malaria
transmission is highly seasonal and the main burden of malaria is
in children [1,2]. Intermittent preventive treatment of malaria in
children (IPTc) is a promising new strategy for malaria control in
such areas [3,4]. Like IPT in pregnant women (IPTp) [5,6] and
IPT in infants (IPTi) [7,8,9,10], IPTc consists of administration of
a treatment dose of an effective anti-malarial drug (or drug
combination) at predetermined time points to a specified at-risk
population, regardless of parasite burden or symptoms. Despite a
growing clinical literature supporting the efficacy of IPTc
[4,11,12] and interest from policy makers in implementing this
intervention, no studies published to date have examined
community perceptions of IPTc or how such perceptions may
facilitate or pose challenges to delivery in countries where the
innovation might be deployed.
A recent systematic review and meta-analysis found that IPTc
administered monthly during the high malaria transmission season
reduced the incidence of clinical malaria by 82% (95%CI: 75–
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87%, p,0.001) [4]. While insecticide-treated bed nets (ITNs) are
the malaria prevention strategy of choice in many countries [13],
many children in malaria endemic areas do not sleep under a net,
and even where ITN coverage is high, malaria morbidity and
mortality may persist [11,12]. To determine the added value of
IPTc in children who slept under a long-lasting insecticide-treated
bed net (LLIN), a double-blind, placebo-controlled, randomized
trial of IPTc was conducted in Burkina Faso and in Mali in 2008–
2009 [11,12]. This trial demonstrated that even with extremely
high use of LLINs (Burkina Faso: 93% [11], Mali:.99% [12]),
IPTc reduced malaria morbidity substantially. In Burkina Faso,
the protective efficacy of IPTc against episodes of clinical malaria
was 70% (95% CI: 66%, 74%) [11] and in Mali it was 82% (95%
CI: 78%, 85%) [12]. Severe malaria was reduced by 69% (95%
CI: 6%, 90%) and 87% (95% CI: 42%, 99%), respectively [11,12].
While pregnant women and infants receive IPTp or IPTi during
existing health service contacts, children under five years of age do
not have pre-existing contacts with the health service at the
necessary intervals to receive IPTc. Thus, IPTc shares many of the
implementation challenges of Vitamin A distribution, polio and
measles vaccination campaigns, and mass drug administration
(MDA) to combat helminth infections. However, unlike these
other campaigns, current IPTc drug regimens require that
children receive tablets on three consecutive days each month,
as single-dose formulations are not currently available. Moreover,
IPTc poses the further challenge of requiring that drugs be given
during the rainy season when travel is most difficult and rural
populations are focussed on farming. An effective implementation
strategy requires more than mere acceptance of the intervention;
local actors need to be motivated and mobilized to take an active
role in implementing IPTc.
The study described in this paper set out to provide insights into
the meanings community members attach to IPTc and to solicit
their recommendations for its large-scale implementation. While
the IPTc and LLIN clinical trial in Burkina Faso and Mali presents
a somewhat artificial context, it also provides a timely opportunity
to examine perceptions of the intervention before large scale
implementation of IPTc is attempted in these settings.
Methods
1. Study setting and conduct of the trial
Detailed descriptions of the study setting, how the trial was
conducted, and its main findings have been published previously
[11,12]. In Mali, the trial was conducted at two rural health
centres located 40 and 45 kilometres southwest of Bamako and at
one semi-urban small town health centre 80 km south of Bamako.
In Burkina Faso, the trial was undertaken in four rural health
centres in Bousse´ District, 45 km north of the capital.
Researchers held meetings with health and local authorities to
answer questions and obtain permission for the trial before
meeting with women at each health facility to explain the trial, to
obtain individual written consent, and to screen children for
eligibility to participate in the trial. Caregivers received a LLIN for
each child. Approximately 6,000 children aged 3 to 59 months
who lived within 2 km of one of the seven health centres were
individually randomised to receive three rounds of IPTc or
placebo over three-day periods in August, September, and
October 2008. Sulphadoxine pyrimethamine (SP) and amodia-
quine (AQ) tablets (or placebos) were administered on the first day
and AQ alone (or placebo) on the subsequent two days. Caregivers
were asked to bring their children to their local health centre for
supervised IPTc administration on all three days each month.
Trial staff weighed children, assigned them to receive a small,
medium, or large tablet, and physically administered the tablet(s)
to the child by crushing them in a spoon for infants or providing
sugar water and sometimes biscuits to older children. The research
team paid one or more CHWs at each site to assist with the
administration and to seek out and remind caregivers of children
who did not attend, which resulted in very few doses missed during
the trial [11,12].
Throughout the 2008 and 2009 malaria transmission seasons,
study children were monitored for episodes of malaria, hospital
admission or death. Children who presented to the health centre
for IPTc administration were examined and, if found to have
malaria, were treated with an alternative antimalarial combina-
tion. Health care was made free at the point of use for all study
participants.
2. Data collection
In-depth, semi-structured, individual interviews (IDIs) were
conducted with caregivers of children under five years old and
Community Health Workers (CHWs) to understand perceptions of
IPTc at the community level and to explore local understanding of
malaria prevention. These participants, as well as additional
caregivers and CHWs, were invited to take part in a focus group
discussion (FGD), in which participants were encouraged to
formulate practical recommendations regarding future IPTc
distribution in their country.
Data were collected six to nine months following implementa-
tion (Mali: May to July 2009, Burkina Faso: June to August 2009),
and so reflected not the immediate response to IPTc, but rather
participants’ views as they approached the new rainy season.
In both countries, interviewers included men and women with
masters’ degrees in sociology and experience in health-related
interviewing in rural areas. In Mali, three junior physicians who
had been involved in delivering IPTc also conducted interviews,
although they did so only in sites where they had not provided care
and were responsible for less than one-third of interviews.
Interviews and FGDs were conducted in Bambara in Mali and
More´ and Malinke´ in Burkina Faso. Themes covered in the
interviews and focus group discussions are presented in Figure 1.
Caregiver interviews were conducted in or near the participant’s
home, while CHW interviews were conducted either at the
participant’s home or at the local health facility, depending upon
the CHW’s preference. FGDs were conducted at or near the
health facility. At each FGD, a single interviewer facilitated the
discussion, while a second observed and took notes, and a third
observed and took care of practicalities. Interview participants
indicated that mixed sex FGDs would be culturally inappropriate
for caregivers but that mixed sex FGDs with CHWs were
acceptable.
3. Sampling
The sample size was set at approximately 90 to 120 interviews
and FGDs across the two countries a priori on the basis that this
would prove neither so large a sample as to inhibit deep, case-
oriented analysis nor so small a sample that it would become
difficult to achieve data saturation, theoretical saturation or
information redundancy [14,15,16].
Participants were purposively selected from amongst the
caregivers involved in the trial and from amongst the CHWs
associated with health posts involved in the trial with the aim of
including a wide range of views and experiences associated with
IPTc and malaria prevention. The caregiver population was
initially defined as the primary female caregivers of all children
under five years of age who were eligible to participate in the trial.
However, preliminary interviews highlighted the key role of male
Qualitative Study of IPTc in Burkina Faso and Mali
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relatives in decision making around child health, and so a smaller
proportion of self-defined male ‘‘caregivers,’’ was included in the
overall sample. The caregiver sample was stratified to include
three levels of participation in the trial: highest participation (child
received all 9 doses without any reminder), moderate participation
(child missed 1–2 doses, or received all doses only after repeated
reminders), and lowest participation (refusal, withdrawal, or
multiple missed doses). Active or placebo status could not be
included in the sampling criteria as epidemiological data collection
was ongoing and researchers were still blinded as to which study
group a child belonged. The CHW population was defined as both
men and women of varying ages already working as CHWs within
the catchment area of each of the health centres included in the
trial. CHWs were selected from villages included in the IPTc
efficacy trial and those from more distant villages which were not
included in the trial.
If an identified person refused or was not available to
participate, a replacement from the same sub-group with similar
characteristics was identified. At the end of each individual
interview, the participant was invited to take part in a group
discussion at a specified time and place later in the week.
4. Data entry and analysis
Data from each interview and each FGD were prepared in a
standardized format, which included basic socio-demographic
information, the interviewer’s own observations and reflections on
the interview, and the verbatim transcript in French based on
digital audio recording(s). The FGD facilitator and the two
interviewers who had observed the FGD collaborated to prepare
the FGD transcript, observations, and participant information. In
most cases, the transcript and observations were prepared within
24 to 48 hours of conducting the interview or FGD.
All data were uploaded into QSR NVivo 8.0 . The French-
language transcripts were coded line by line using detailed themes
and sub-themes identified a priori as being relevant to the initial
research questions, as well as using detailed themes and sub-
themes that emerged from the data, including the interviewers’
observations, and from theoretical and empirical literature.
Attributes such as country, sex, number of children in the trial
and number of doses each child received were associated with each
interview and (in most cases) FGD participant. Active or placebo
status was revealed and employed in the analysis only after
thorough coding. The frequency and content of sub-themes were
assessed for similarities or differences across different attribute
values, for example comparing the frequency of reporting side
effects amongst children who received active IPTc compared with
those who received placebo. Illustrative quotations have been
translated into English and are included in the results.
5. Ethical considerations
Both the clinical trial and this qualitative sub-study were
approved by the ethics committees of the relevant research
institutions in the UK (London School of Hygiene & Tropical
Medicine), Mali (Malaria Research and Training Center), and
Burkina Faso (Centre National de Recherche et Formation sur le
Paludisme).
Written informed consent was obtained from all participants
before participation in interviews and focus groups and was
reconfirmed orally before digital audio recording. For those who
participated in both an interview and a FGD, consent was
obtained separately for each. Where participants had difficulty
reading a full page of text, a member of the research team read out
the consent form and a literate community member unconnected
with the study (usually the local school teacher) acted as an
independent witness of the consent process.
Results
Seventy-two interviews and 23 FGDs were conducted with 179
participants (Table 1). Twenty-seven of the 58 CHWs who
participated in an interview and/or FGD (47%) also identified
themselves as a caregiver of at least one child who had participated
in the trial; they are categorized as CHWs rather than caregivers.
The trial status of the children of these CHWs is shown in
Table 2. Interviews lasted an average of 30 minutes and FGDs
lasted approximately one hour.
The trial context was found to play an important role in
mediating perceptions of IPTc. Therefore, we focus first on
perceptions specific to the trial context.We then explore five
themes which, while mediated by the trial context, would also be
relevant for future IPTc implementation: perceptions of IPTc
tablets and side effects, their compatibility with existing under-
standing and experience of childhood illness, the social context of
participation, and perceptions of tablet distribution during the
trial. Finally, participants’ own recommendations as to how IPTc
should be distributed in future are presented.
Results from the two rural sites in Mali and four rural sites in
Burkina Faso were strikingly similar. The most notable differences
were not between the two countries, but rather between the six
rural sites and the single, semi-urban site. Differences in
perceptions based on these and other participant characteristics
are highlighted where they emerged.
Figure 1. Themes explored in individual interviews and focus group discussions with caregivers and CHWs.
doi:10.1371/journal.pone.0032900.g001
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1. Interpretation of IPTc as part of a package of trial
activities
Perceptions of the trial, which was known locally as ‘‘the
project’’ or ‘‘the malaria project’’, were overwhelmingly favour-
able. Participants tended to conceive of the trial as a single entity.
Opinions based on experiences of one trial-related activity, such as
provision of free curative care or LLINs, were sometimes directly
attributed to another activity or to ‘‘the project’’ or ‘‘the malaria
project’’ as a whole. Aspects of the trial which were specific to the
trial context thus influenced overall perceptions of ‘‘the project’’
and even perceptions of the IPTc tablets and their distribution.
Two aspects of the trial engendered concern amongst some
participants at the start. In the semi-urban site in Mali, the very
concept of a trial seemed to raise concerns, as rumours spread that
the IPTc tablets would cause infertility, that the medicines were
expired, and that the research team would sell children’s blood. A
few residents also seemed to have been under the (false) impression
that a new drug was being tested. Nearly all of the small number of
eligible families who refused to participate in the trial and 29 who
formally withdrew consent were in this town, the only non-rural
trial site in the study [12]. Men appeared to play a significant role
in these decisions. While this town had experience of other trials,
so too did some of the other sites; the key difference was the town’s
far greater socio-economic diversity. An educated local leader
refused to allow his children to participate and actively
discouraged his neighbours.
… the children started taking the medicines, and he came and said ‘you
mustn’t accept, you, you’re educated, and your children will be guinea
pigs.’
Table 1. Number of individual interviews, focus group discussions (FGDs), and participants by country and sex of participant.
Mali Burkina Faso TOTAL
Female Male Female Male
CHWs Individual Interviews 5 7 2 10 24
FGDs Groups 4 (mixed sex) 4 (mixed sex) 8
Participants 10 16 8 20 54
Caregivers Individual Interviews 17 7 15 9 48
FGDs Groups 4 3 4 4 15
Participants 29 23 24 24 100
TOTAL Transcriptsa 47 48 95
Participants 93 86 179b
aThe total number of transcripts is the sum of individual interviews and focus groups conducted.
bThe total number of participants in the study (n = 179) is less than the sum of participants in individual interviews (n = 72) and participants in the FGDs (n = 154) because
some (n = 47) participated in both an individual interview and a FGD.
doi:10.1371/journal.pone.0032900.t001
Table 2. Trial status of the children of participating caregivers.
IPTc status of participant’s child(ren) CHWs** Caregivers TOTAL
Mali All received active IPTc 3 (30%) 21 (32%) 24 (32%)
Mixed – at least one received placebo and one active 4 (40%) 14 (22%) 18 (24%)
All received placebo 3 (30%) 19 (29%) 22 (29%)
Refused 0 (0%) 9 (14%) 9 (12%)
Status unknown 0 (0%) 2 (3%) 2 (3%)
Burkina Faso All received active IPTc 5 (29%) 24 (43%) 29 (40%)
Mixed – at least one received placebo and one active 5 (29%) 16 (29%) 21 (29%)
All received placebo 7 (41%) 16 (29%) 23 (32%)
Refused 0 (0%) 0 (0%) 0 (0%)
Status unknown 0 (0%) 0 (0%) 0 (0%)
TOTAL All received active IPTc 8 (30%) 45 (37%) 53 (36%)
Mixed – at least one received placebo and one active 9 (33%) 30 (25%) 39 (26%)
All received placebo 10 (37%) 35 (29%) 45 (30%)
Refused 0 (0%) 9 (7%) 9 (6%)
Status unknown 0 (0%) 2 (2%) 2 (1%)
TOTAL 27 121 148
**CHWs without children eligible for the trial are excluded from this table.
doi:10.1371/journal.pone.0032900.t002
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–Female caregiver, FGD, Mali, mixed active and placebo (ML
FGD08-P3)
Well, really for a farmer, if you’re told that a new medicine has come,
that they’re going to test it on you, that’s a problem. That’s why a lot of
people withdrew.
–Male caregiver, FGD, Mali, refusal (ML FGD11-P6)
Yet, after observing the trial over the course of the malaria
season, many of the caregivers who had refused or withdrawn their
children and those whose children had not been eligible to
participate actively lobbied ‘‘to be included in the project.’’
The references in the consent forms to the need for finger-prick
blood samples also raised some concern in all the sites, although
these did not seem to lead to refusals or withdrawals. While many
caregivers and CHWs described blood samples in a neutral or
positive light, explaining that the ‘‘doctors needed to look in the
blood for malaria,’’ some caregivers were concerned that the blood
would be sold or that the blood loss would make their child
‘‘weak’’ or ‘‘bring another disease.’’ These fears over the quantities
of blood that would be taken suggest that some believed that
participation in the trial would require the collection of larger
samples through venipuncture.
Two other aspects of the trial, the provision of free LLINs and
free curative care for trial participants, contributed positively to
perceptions of the trial. When the trial team distributed LLINs at
the start of the malaria season, many women arrived at the health
centre in the middle of the night to ensure that they would not miss
out, demonstrating the high value placed on this ‘‘gift’’ despite low
levels of prior usage. In expressing enthusiasm for IPTc or for ‘‘the
project’’ in general, participants often explained the advantages in
terms of the benefits of the free curative care.
What the tablets have brought in terms of benefits can’t all be cited. It
helps families in different ways. Someone can be sitting there without
100 francs [$0.21, 2009 USD] and gets his child treated for free.
The cock that you were going to sell to treat your child, you can keep.
– Male CHW, IDI, Burkina Faso (KK00)
The trial team encouraged prompt care seeking, but many
participants specifically cited the removal of this financial barrier
as increasing their utilization of curative health services. In Mali,
where research team doctors were on site 24-hours a day,
participants particularly appreciated the willingness of the doctors
to provide care at any hour ‘‘nicely and with respect’’ and without
charging fees.
2. Perceived impact and interpretations of IPTc tablets
and side effects
When asked specifically about ‘‘the tablets your child received
nine times last year in the malaria season, three times in a row in
August, three times in a row in September, and three times in a
row in October,’’ opinions were very favourable. Most participants
commented on reductions in morbidity and mortality, but these
positive responses were evident amongst both those caring for
children who had received the placebo and those whose children
had received the active drug. None reported observing differing
levels of effectiveness of the tablets for different children nor did
they attribute differences to placebo tablets. Indeed, in all the
interviews and discussions conducted, only one person, a CHW,
alluded to the fact that half the participants received placebo
tablets. Nonetheless, caregivers of children who had all received
active IPTc were considerably more likely to attribute the
morbidity reductions specifically to IPTc, whereas those whose
children received placebo were more likely to attribute benefits
more vaguely to ‘‘the project.’’
… since mine received the tablets, he has not fallen ill any more. He
hasn’t even complained of headaches.
–Female caregiver, IDI, Burkina Faso, active IPTc (KH04)
The tablet that was given to children, ha, people have really seen a lot of
benefits from it. We have really seen benefits from it, because at the time
of the administration, my child didn’t fall sick. We took all the three
doses, my child hasn’t had malaria, we haven’t found any dizziness.
–Female caregiver, IDI, Mali, active IPTc (BS04)
The absence of illness and the presence of ‘‘good health’’ was a
widely observed (non-)event. While caregivers appreciated the
decrease in child illness, they also appreciated its positive
consequences for themselves.
… here now in Djoliba malaria has decreased. I wouldn’t say that it is
completely gone, but, if it pleases God, we thank God, the number of
deaths of children has decreased a lot. In the past, we couldn’t even farm
because of the deaths.
–Male CHW, IDI, Mali (FD01)
The tablets have spared us from many worries. Thanks to the tablets,
we no longer take our children to the health centre because they are no
longer sick. We can also take care of our field work.
–Male caregiver, IDI, Burkina Faso, mixed active and placebo
(OD16)
Most caregivers did not offer any particular explanation of how
IPTc worked, but a few caregivers and many CHWs described
IPTc as ‘‘fighting’’ against invisible ‘‘germs of disease’’ in
children’s bodies. Only a small proportion of caregivers referred
to IPTc as vaccination or immunization:
I took my child for the malaria vaccination because … malaria is a very
contagious disease that can kill in an instant … even if you don’t take
the medicine [IPTc], if you are […] protected by the bed nets against
mosquitoes, it’s very likely that you won’t get sick with malaria.
–Female caregiver, IDI, Mali, placebo (SD13)
Questions did not specifically seek opinions on the drug
combination, SP and AQ, but participants did not raise the issue
either, suggesting that opinions of IPTc were not linked to pre-
formed opinions about the IPTc drugs.
During the consent process for the trial, caregivers were warned
of the potential side effects of IPTc, which included vomiting,
diarrhoea, and fever, and for which they could receive treatment at
the health centre. For some, this warning was reassuring, and so
they were not alarmed by the side effects when they occurred, while
others were concerned or bothered enough about the side effects
that they were reluctant to return to the health centre for subsequent
IPTc doses. These responses related to how the caregivers
interpreted the side effects. Several CHWs and caregivers described
side effects as the product of the interaction between the IPTc drugs
and disease in the body – and therefore not as a risk, but a positive
sign that the medication was ‘‘working’’ – which was a common
understanding of the action of traditional remedies. A few caregivers
explained that children need to ‘‘get used to’’ IPTc.
P7: Although they were told about the reactions the medicine can cause,
certain mothers refused to give the medicine to their children. They say
Qualitative Study of IPTc in Burkina Faso and Mali
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that it causes this and that to my child, although we were well informed
about that before the start of the project. It’s written for those who can
read, and repeated to those who don’t know how to read, but with all
that some people were afraid. But after the benefits were seen, it cured
malaria in a lot of children.
P2: Me, I didn’t see these reactions in my children, no vomiting, no
diarrhoea.
P3: Even if the child vomits, you are asked to bring the child to the
centre.
P2: Because if you are having the treatment and when the medicine
arrives at the disease, it causes reactions, so that’s what provokes
diarrhoea and vomiting.
–Female caregivers, FGD, Mali (ML-FGD02)
Any food that you’re not used to, if you eat it before your intestines get
used to it, it hurts you. And, it’s the same with medicines for children.
We are given the medicines, if the children have diarrhoea, they say
‘‘don’t hesitate, come have the anti-diarrhoeics’’ … this is how as they
go along the children get used to the medicine.
–Female caregiver, FGD, Mali, placebo (ML-FGD02-P6)
The caregivers interviewed were more likely to report side
effects in Mali than in Burkina Faso, though reports of side effects
were uncommon overall. Caregivers were equally likely to report
that their child or children had experienced side effects regardless
of whether the child had received active or placebo tablets. These
results appear to contradict the quantitative results reported in the
trial papers, which found that vomiting was more frequent in
children who had received IPTc and far more frequent in Burkina
Faso than in Mali (27.6% vs. 4.0% of children receiving active
IPTc vomited at least once) [11,12]. One explanation for this
anomaly may be the purposive rather than statistically represen-
tative sampling used in the qualitative data collection. It is also
possible that caregivers whose children received active IPTc were
less likely to report negative aspects of IPTc, either because their
positive overall assessment of IPTc coloured memories or
interpretations of side effects many months before, or because
they did not want to say anything that might negatively affect
future IPTc implementation.
3. Compatibility of IPTc with existing understandings and
practices
IPTc in itself was compatible with existing understandings,
practices, and experiences of childhood illness. Participants’
syncretic approach to health meant that adopting IPTc did not
mean rejecting existing practices or understandings; IPTc could, in
effect, be ‘‘added’’ without necessarily displacing existing practices.
Most participants identified mosquito bites as a cause of
malaria. As found in previous studies [17,18], CHWs and
caregivers in both countries also attributed malaria to dirty
hands and food, certain (cold) foods, and divine will. When asked
what they do to prevent malaria in their children, a few
caregivers explicitly said that prevention was not possible, but
most cited a number of both preventive and curative strategies,
including bed nets, ‘‘hygiene’’, insecticides, ‘‘taking the child to
the health centre when he is ill,’’ and wrapping children warmly.
The study communities repeatedly and spontaneously cited their
past experiences with chloroquine chemoprophylaxis (known by
its brand name, ‘‘nivaquine’’), with which they were very
familiar:
… we were told not to give nivaquine to children, but in the past, I used
to buy a lot of nivaquine during the rainy season. I kept it at my expense.
Each time I used to give these nivaquines to the children until the dry
season. That’s what used to keep them from falling ill.
–Male CHW, IDI, Mali (BS01)
Many caregivers were, therefore, already familiar with using
tablets both to treat and to prevent malaria and commonly
employed a number of different malaria control strategies
simultaneously.
Some people described in detail their conception of the
complementary nature of LLINs and IPTc:
I think that the two methods used together is better, because in sleeping
under the bed net, the child can find himself outside of the bed net and
thus expose himself to mosquitoes. But, if the bed net is accompanied by
a tablet, the body is immunized to fight against the germs of disease.
–Male caregiver, IDI, Burkina Faso, placebo (OD01)
IPTc was thus seen as highly compatible with and complemen-
tary to LLINs; there was no evidence that people perceived them
as substitutes. While this attitude is likely to have been partly a
reflection of the research team’s sensitization messages encourag-
ing bed net usage, it also seemed to fit in with a more general
perception of the need for new and better strategies to combat
malaria. In discussing the benefits of IPTc, several participants also
explicitly expressed openness to any strategy that could prevent
malaria or improve health.
The last words I have to say are that really, this medicine [IPTc] is
very important. I can’t say how important it is. Since it was given to us,
there has been good health. We really feel that a lot, we like this
medicine a lot. If another one is found in addition, that’s what we’re
looking for.
–Female caregiver, FGD, Mali, IPTc status unknown (ML-FGD04)
While participants did not clearly distinguish preventive from
curative activities, they did draw a clear distinction between
‘‘modern,’’ ‘‘Western’’ or even ‘‘white people’s’’ medicine and
‘‘traditional’’ medicine. Very rarely did participants cite traditional
practices initially, but when prompted specifically, and sometimes
when asked about traditional preventive practices that ‘‘other
people’’ use, they cited placing leaves in hot water for the sick child
to bathe in, drink, or inhale the vapours and burning the shells of
Shea nuts or, less frequently, cow dung, to fill the house with
smoke and chase mosquitoes away. Some said that ‘‘times have
changed’’ and that traditional medicines are no longer effective
because children ‘‘have become modern’’, because ‘‘people’s
blood isn’t the same now’’, or because ‘‘people’s food has changed
now’’, but none of the participants indicated that use of one type of
preventive activity precluded use of another.
4. Participation in IPTc as a social act
Perceptions of and participation in IPTc were also shaped by
several key aspects of the social context, independently of personal
views and experiences of IPTc or the trial. Trust in and respect for
authorities, including formal health workers, emerged as an
important motivator for adopting IPTc. Older participants in
Burkina Faso in particular described the distribution of IPTc and
LLINs as ‘‘a gift,’’ citing the importance of accepting and the
dishonour to the community of refusing a gift. Both caregivers and
particularly CHWs described participation and adherence in
terms of ‘‘obeying’’ or ‘‘disobeying,’’ suggesting a sense of
obligation to comply. There was no evidence that the trial team
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coerced participation, but caregivers and CHWs both seemed to
place a significant social value on respecting hierarchical social
structures, which were seen to have sanctioned IPTc and the trial
as a whole.
As it’s the nurses who gave it, it’s required that you use it. If you take
the bed net and you say that you will no longer go to the health centre
[for the IPTc tablets], that, too, is not right.
–Female caregiver, IDI, Burkina Faso, placebo (KK02)
… I accepted because they cannot come here without going through our
authorities to explain it to them. And we are under them [the
authorities], and someone who is your authority, if he sends you someone
who is going to care for you, this latter person must know something
[…] He’s not going to send you an idiot.[… ] Our authorities love us
…
–Male caregiver, IDI, Mali, placebo (SD08)
The degree to which participation was an observable social
activity also seemed to encourage participation.
P1: Me, all my neighbours came.
P5: We come as a group. When one woman goes out, she calls the
others and we come to the health centre together.
–Female caregivers, FGD, Burkina Faso (BF-FGD01)
One man who had initially refused for his children to participate
was reassured regarding the safety of IPTc by the observation that
wealthy community members were participating.
My case is a lesson and advice … If it causes sterility, the rich people
are signing up their children because they don’t love their children? They
love them! . . when I realized the lie, I ran [to be included], but you [the
study team] refused. I can’t force you, but I would like to enter [the
trial].
–Male caregiver, IDI, Mali, withdrew from trial (SD09)
While sensitization activities focussed on women, male caregiv-
ers emerged as playing an important role in decision-making in
both countries, whether they were for or against participation.
Several of the cases of refusal or withdrawal were linked to a male
family member, rather than the mother.
It’s true that the child belongs to both of you, but as a woman, you can
decide to take the child to the health centre and your husband wants you
to go to the fields. If you disobey and you go to the health centre, your
husband will say that you disobeyed him and you will have difficulties
to come back home… it doesn’t make you happy, but you resign yourself
to your husband’s will … If the child is sick you can take him quickly
to the dispensary without your husband’s authorisation. Other than this
urgent case, men don’t accept.
–Female caregiver, FGD, Burkina Faso, IPTc status unknown (BF
FGD01)
It was a bit difficult for me because people went and told my father-in-
law bad rumours, that this work, this thing, wasn’t good… He told us
to abandon this thing [the trial] … That’s why we didn’t continue the
rest of the trial.
–Female caregiver, FGD, Mali, mixed active and placebo (ML-
FGD06-P1)
The child’s father said that if the child is not included in this thing [the
trial], he is going to divorce me.
–Female caregiver, FGD, Mali, mixed active and placebo (ML
FGD08-P4)
5. Perceptions of IPTc delivery in the trial
Many male and female caregivers expressed satisfaction with
distribution of IPTc at the health centre. One advantage that
emerged was that it provided an opportunity for contact with a
health worker, which both instilled confidence in IPTc and gave
the opportunity for children to be seen by a health worker.
Because even we women, there are women who have children, but they
don’t know that their children are sick. But there, if a woman brings her
child and the health workers look at it, they can detect the child’s illness.
–Female CHW, FGD, Burkina Faso (FGD06-P6)
In a number of cases, participants also compared the effort of
taking their children for IPTc administration with the conse-
quences of them falling ill and the importance of child health.
We know that if we’re told to evacuate him to [the district hospital at]
Bousse´ once, it’s really not easy. So,[taking IPTc tablets] 9 times is
easier than Bousse´ once.
–Male caregiver, FGD, Burkina Faso (BF-FGD02)
P1:… health is worth more than anything. It’s true that it’s the season
for [field] work, but it’s because there is health that we can work -
P5: - [interrupting] it’s true, if there is not health, we cannot work […]
P4: If your child is sick, you take him to the health centre even if it’s in
the harvest season. Too bad for the field work. To preserve your child’s
health, you must not worry about field work. The health of the child is
the priority.
–Female caregivers, FGD, Burkina Faso (BF-FGD01)
The most common reason for a missed dose in both countries
was that the child had travelled with his mother to another area, or
that the person who would normally take the child to the health
centre had travelled, even though the child was still at home. In
addition, many children were not included in the trial because
their family intended to travel, which was especially common
amongst nomadic Peuhls in Mali and amongst migrant labourers
in Burkina, who often travelled to Coˆte d’Ivoire.
Although only those families living fewer than 2 km from the
health centre were included in the trial, the most frequently cited
areas of dissatisfaction with the distribution of tablets were the time
spent travelling to and from the health centre, and the time and
experience of waiting at the health centre for many hours, often in
the sun, on the distribution days. These were cited as reasons why
some children missed doses during the trial and why some
caregivers only came after repeated reminders.
The method of taking [the tablets] was difficult because the day they
told us to come, there were a lot of people who came out and filled the
area all around the health centre. Nobody was able to work that day,
you understand. There were fights and insults.
—Female caregiver, FGD, Mali, IPTc status unknown (ML-
FGD04)
Of course it’s difficult! [shouted] It’s not easy to put a child on your
back and to carry the other to the health centre. If you don’t eat and you
must carry two children and walk to the health centre, it’s tiring. When
you arrive, you feel dizzy. [laugh] After, you’re accused of refusing to
respond to the convocations.
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–Female caregiver, IDI, Burkina Faso, placebo (KH11)
Women who were the only woman in their household found it
particularly difficult to wait for IPTc each day because they
needed to return home to prepare the family’s meal. A number of
caregivers reported asking friends or neighbours to bring their
children, but they were not always successful. In Mali in particular,
women who were reluctant to seek IPTc at the health centre were
often described as ‘‘lazy’’ or lacking in ‘‘courage’’:
P4: Mothers know the importance of the treatment, but they are lazy,
they are not courageous –
P7: They know the importance of the treatment, but leaving their
fieldwork, especially the groundnut harvest, in favour of the child’s
treatment, that’s difficult. And then with the approach of the harvest …
–Female caregivers, FGD, Mali (ML-FGD02)
6. Participants’ recommendations for IPTc distribution in
future
In FGDs, caregivers and CHWs discussed a number of
strategies to ensure that all children in the catchment area of
each health post, including those living in more distant villages,
would receive all nine doses of IPTc if the health service were to
decide to distribute it in future. Key issues that emerged included
sensitization, the location of distribution, the role of formal health
workers and CHWs, and the role of caregivers.
To overcome initial scepticism regarding a new intervention,
participants in both countries recommended that information
should be provided well in advance by radio and in person by
CHWs. Many focussed on the visible presence of health workers,
and in some cases community leaders, as an important factor
instilling confidence in the intervention.
Many CHWs and caregivers in both countries argued that
distribution needed to be ‘‘closer to the population’’ than in the
trial. While a few participants favoured continuing distribution
only from the health post and others recommended a door-to-door
strategy, distribution from a fixed location in each village or
neighbourhood was supported most widely, especially if those
living nearby could continue to receive IPTc from the health post.
Participants preferred fixed locations in each village because
CHWs would not waste time going to homes when people were
not there, caregivers could stop by at a time of day convenient for
them, and it would be easier to organize. One CHW also
advocated fixed distribution points to prevent fraud:
It’s so that it will be in front of everyone’s eyes! Because we all who are
sitting here in one place, some will verify papers, attendance, and other
will give the tablets! Like that, there can’t be any fraud!
-Male CHW, FGD, Burkina Faso (BF-FGD00-P1)
Another CHW suggested combining fixed location and door-to-
door distribution:
… if we find that there are people who haven’t come, we can find them
at home to give them the tablets!
–Male CHW, FGD, Burkina Faso (FGD06-P2)
Preferences for a particular distribution strategy were closely
associated with perceptions of the appropriate role of formal
health workers and CHWs. Many caregivers and CHWs in both
countries considered a key advantage of distribution from the
health centre or from a fixed point in each village to be that it
would allow for the visible and reassuring presence of a formal
health worker. Some caregivers in both countries expressed their
lack of confidence in CHWs particularly strongly, although a
CHW in Mali indicated that willingness to follow CHWs varied
between areas.
P4: … if a CHW sets up in my neighbourhood to give the tablets
without the assistance of a health worker, I will refuse these tablets. I
won’t have confidence! […]
P6: We who are close, we can come to the health centre to take the
tablets with health workers. For those who are far away, it would be
better if a CHW and a health worker go do the distribution. There are a
lot of illiterates amongst the CHWs. Without the help of a health
worker, it would be difficult …
–Male caregivers, FGD, Burkina Faso (BF-FGD08)
Well, as we are from the [rural] village, I can say that here [in the town
centre] it’s more difficult than for us. Because if you say to people to
come out to take your medicine on this day, the day you say, it’s very
unlikely that people will miss this day … there are a lot of problems in
town, but with us in the bush, it’s not the case.
–Male CHW, FGD, Mali, (ML-FGD05-P3)
Regardless of their preferred strategy for delivery of IPTc, both
CHWs and caregivers emphasized the importance of training the
CHWs for their tasks. Discussions with CHWs revealed that most
did not have experience in or the equipment for weighing
children, although they were familiar with measuring height for
dosing albendazole as part of MDA to combat helminth infections.
Several CHWs suggested that if children were enumerated in
advance, as was done in the trial, coverage would be higher and
distribution would be simpler, regardless of the distribution
method selected.
The CHW needs to have a list with all the information about each
child: his weight, his height, the dose of tablet that he needs. The
following day and the day after, it will be easy for the CHW to give the
remaining doses to the child.
–Male CHW, FGD, Burkina Faso (BF-FGD09-P3)
The question of who should administer AQ tablets on the
second and third day each month elicited the firmest opinions.
The vast majority of male and female caregivers and CHWs were
against proposals to leave the two AQ tablets with the child’s
caregiver to administer on the second and third days. Instead, they
proposed that either a CHW or a health worker should administer
these doses. The most common reasons given were that the
caregiver would forget or would not be able to administer the
tablet, but a number of participants also raised concerns about
how caregivers could re-administer tablets at home if their child
vomited or spat out the tablets. A few participants also cited doubts
about caregivers’ ability to store tablets correctly.
If it’s given to people, some may not give it, but if you ask them, they
may say out of shame that they’ve give it when they haven’t give it …
Thus, if the nurses or CHWs give it at fixed points, that’s better than
giving [the tablets] to parents.
–Male caregiver, FGD, Burkina Faso (BF-FGD02).
P5: Well, the children are also more afraid of doctors than their parents.
If parents put them [the tablets] in their mouths, they may refuse. But if
it’s doctors, they won’t. And the medicine will be wasted -
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P1: - and the distribution of albendazole that we do here, you
yourselves, you see them vomit and do everything, but even if they vomit
they’re given more until they swallow. What mother can handle that
with her child?
P5: All mothers love their child. If the child refuses to swallow, that’s it
–
P3: It’s not a question of loving, it’s not that, it’s –
P1: It’s courage.
P3: Everyone wants her child to get well. If it’s said that this medicine
cures him, you give it, but they are not courageous… it’s not easy.
P5: They’re not courageous.
–Female caregivers, FGD, Mali (ML-FGD08)
Participants cited caregivers’ experience in giving tablets at
home to treat illness both in support of and against asking
caregivers to administer IPTc at home.
… if the child has a fever, they give him [the medicine], but once the
child is better, the woman forgets the rest of the treatment [said while
banging his hand on the table for emphasis]
–Male caregiver, FGD, Mali, refusal (ML-FGD09-P1)
For the two following days, the parents can give the tablets because
they’re used to giving tablets at home when the child is sick. But if the
child vomits the tablet, that’s the problem!
–Female caregiver, FGD, Burkina Faso, IPTc status unknown (BF-
FGD10)
Opinions were more evenly divided as to whether mothers or
fathers should be relied on to provide these doses; while women
and men each generally considered themselves more capable,
many agreed that both men and women should receive
information on how to give the tablets.
Discussion
While Rogers finds that preventive innovations tend to diffuse
slowly because their relative advantages are difficult to see [19],
participants in this qualitative study quickly observed the absence
of malaria in children participating in the trial. This perceived
reduction in morbidity was not always attributed specifically to
IPTc, but sometimes to the trial more broadly. However, it
emerged as an important driver of participation, and adherence to
IPTc was very high. Figure 2 summarizes the main barriers and
facilitators to uptake of IPTc in this trial. Results from the two
rural sites in Mali and four rural sites in Burkina Faso were
strikingly similar; the most notable differences were between the
six rural sites and the single, semi-urban site. Many of the themes
that emerged echoed those identified in recent studies of the
acceptability of IPTi in six African countries [20] and of the
acceptability of IPTp and intermittent screening and treatment
(IST) during antenatal visits in Ghana [20]. This study presents
findings from francophone West Africa, which was not included in
either study of IPTi or IPTp, broadening the scope of
investigations into the acceptability of IPT. While the results of
this study cannot be used to reach generalized conclusions about
how IPTc should be delivered in all settings, Figure 3 highlights
several aspects of IPTc implementation that are modifiable, of
importance to community members, and likely to affect coverage.
A number of contextual factors favoured uptake of IPTc in the
trial. The intervention was compatible with perceived needs and
its effects were observable because of the high efficacy and uptake
of the intervention and the high (perceived and real) reduction in
the incidence of malaria. The rate of adoption of IPTc might,
therefore, be lower in settings where the incidence of malaria is
lower or where caregivers are satisfied with their existing malaria
control strategies. IPTc also resonated with previous experience in
these sites of chloroquine chemoprophylaxis and anthelminthic
MDA, and so the concept of providing tablets to children without
clinical symptoms of malaria did not raise concerns. IPTc fits in
with ideas around the importance of children’s health and multiple
malaria aetiologies. Other studies [17,18] have suggested that the
idea that malaria may have multiple aetiologies can lead people to
believe that LLINs will not be fully protective; this misconception
may in fact aid complementary uptake of IPTc without reducing
use of bed nets. Indeed, a syncretic approach to health in other
African settings has been shown to promote complementary use of
multiple disease prevention strategies, such as vaccination and
traditional talismans [21,22,23,24]. While this approach to health
may affect treatment choices [21,23,24], there was no evidence
that use of IPTc would inhibit care-seeking. In common with the
findings from IPTi studies, which reported that some mothers
viewed the side effects of vaccines as signs that they had ‘‘worked’’
[20], we also found that some caregivers interpreted side effects of
IPTc as a positive sign that the treatment was effective ‘‘when the
medicine arrives at the disease’’, or as a sign that the child needed
to ‘‘get used to’’ IPTc. In contrast to findings in the IPTi studies
[20,25,26], participants did not express any concerns about the
specific drug combination used.
Social norms and structures in both countries encouraged trust
in, respect for, and compliance with authority figures in general
and health staff in particular. This facilitated initial willingness to
try IPTc, when none of the community members had prior
personal experience of this approach to malaria control. The
initial refusals and withdrawals in Mali, though small in number,
were concentrated in an area of greater socio-economic diversity
with more educated residents, and seemed to reflect a degree of
scepticism regarding the trial, which could also affect willingness to
try a new intervention. This motivation to comply with sanctioned
health activities also emerged in the studies of IPTi [20] and in the
comparison of IPTp with IST [27]. A growing literature around
the ethics of trial participation has explored the important role of
social relations in trials [22,28,29] and found that ‘‘interactions
and relationships between researchers and community members,
and within the community, play a critical role in participants’
perceptions of a study’’ [28]. Outside a trial context, other authors
have noted that a sense of ‘‘group citizenship’’ [30] and respect for
authority can motivate participation in health campaigns. In such
cases, participation is related less to the perceived characteristics of
the innovation itself and more to the intangible social benefits of
participating and being seen to participate. The generalizability of
our results and the speed of initial adoption of IPTc would,
therefore, likely be closely associated with the level of trust and
respect for the institution and individuals seen to implement the
intervention and the extent to which caregivers felt a sense of
obligation to their community to participate.
The study highlights a number of measures that could facilitate
uptake of IPTc at scale. The distribution method used in the trial,
which required all participants to attend the health facility on
three consecutive days each month for three months, would not be
feasible for children living in more distant villages and was
problematic for some of those living even quite close to the health
centres involved in the trial. A small-scale study in Ghana
compared delivery of IPTc at fixed locations in villages with a
facility-based delivery strategy and concluded that ‘‘to maximise
the impact of IPTc, both delivery systems may be needed in some
settings.’’ [31] In The Gambia, a larger study found that delivery
through CHWs was both more effective and less costly than
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delivery through monthly outreach visits by a team of health
workers [32]. In both these studies, as well as in a large-scale study
in Senegal, caregivers were asked to administer the second and
third doses of AQ to their children at home, while in our study,
both caregivers and CHWs in Burkina Faso and Mali expressed
concern over such an approach and said that they would prefer
that a CHW or health worker administer all tablets. Further
studies will be needed to compare the most appropriate
distribution strategy for a given context, both initially, and once
community members and health workers have become familiar
with the new strategy. As also highlighted in a study of IPTi [20],
development of appropriate single-dose formulations for IPTc
would greatly facilitate administration and would likely permit
higher, more equitable, and more cost-effective coverage of the
intervention. Measures may also be needed to address the
challenges of highly mobile populations, especially if IPTc were
to be administered in some areas and not in others.
Enthusiasm for IPTc was high in the trial in part because of its
association with distribution of free LLINs and of free, high-
quality, curative care, as noted in other trials [20,22,27,29]. From
the perspective of most caregivers and CHWs, ‘‘the project’’
consisted of more than simply receiving IPTc; it encompassed the
entire package of trial activities, including IPTc, free LLINs, and
free high-quality curative care, as well as blood tests and home
visits for some families. In the language of the theory of innovation
diffusion, ‘‘the project’’ therefore constitutes a ‘‘technology
cluster’’ [19] comprised of several interrelated innovations. A
similar introduction and marketing of IPTc as part of a package of
effective strategies could facilitate adoption of all elements of the
package. While scaling up any one of these strategies presents a
range of challenges [33,34,35], uptake and enthusiasm for IPTc
alone could be lower if it were introduced separately from free
LLINs or free curative care, for which demand was already very
high.
Caregivers in a real-world context could also perceive a greater
relative advantage to taking IPTc than seen in this trial. Rumours
that blood drawn as part of the study would be sold made some
people reluctant to participate in the trial. This concern about
collection of children’s blood for trial purposes has been widely
Figure 2. Key facilitators and barriers to IPTc uptake in the trial.
doi:10.1371/journal.pone.0032900.g002
Figure 3. Questions to consider in planning an IPTc distribu-
tion strategy.
doi:10.1371/journal.pone.0032900.g003
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discussed [22,23,27,29,36]. However, the perception of reduced
morbidity and mortality convinced some caregivers who had
initially refused IPTc to state that they would participate in an
IPTc programme in future.
While issues around communication were not actively pursued
in this study, the need for a single, locally-intelligible name for
IPTc emerged. The French name employed in Senegal,
‘‘Pre´vention Saisonnie`re du Paludisme’’ (‘‘Seasonal Malaria
Prevention’’) or ‘‘PSP,’’ effectively differentiated IPTc from
curative treatment in that setting. However, the appropriateness
of the French language and of this particular name would need to
be explored within a broader social marketing approach before
adoption of this term in Burkina Faso and Mali. A World Health
Organization Technical Expert Group has recently recommended
‘‘Seasonal Malaria Chemoprevention’’ (SMC) as a suitable English
language descriptor. While communication about the trial targeted
women, our research revealed that men could play an important
role both at the decision-making stage and in ensuring that their
children actually received IPTc, a finding consistent with studies of
IPTi [20]. More active targeting of communication about IPTc to
men could help to dispel negative rumours and could also be used
to encourage more active and practical male participation in the
health of their children.
This study benefitted from a structured research process which
allowed comparable data to be collected in two countries. We
found that interviewers required a very detailed understanding of
the clinical trial design and practical aspects of IPTc implemen-
tation in order to probe effectively, and that a workshop with study
team physicians was an effective forum for sharing this knowledge.
We found that for a number of female caregivers, expressing an
opinion even on this non-sensitive, recent experience was new and
challenging, while the opportunity to participate in both an
interview and a FGD seemed to set participants at ease and
encourage expression. Male and female CHWs expressed
themselves more readily.
A key advantage of conducting qualitative research during a
trial phase of a new intervention is that it provides an opportunity
to ensure that there are no unchangeable aspects of the innovation
that are likely to prevent its widespread adoption, and to identify
potential modifications to the intervention that could maximize its
uptake. Rather than attempt to dissociate perceptions from their
context, this paper has focussed on understanding the perceptions
of IPTc and on making specific recommendations which can be
applied to future efforts to roll out the innovation.
This study has a number of limitations. Although the trial
included seven sites in two countries, only limited geographical
areas in these two countries were studied. While some degree of
triangulation was possible, results were largely based on what
participants reported, which is not always reflective of their
thoughts, intentions, or future behaviour. Although participants
were told that they would receive no direct benefits as a result of
the interviews, association of the interviewers with the trial team
may have increased participants’ desire to respond positively in the
hope that doing so might enable them to continue to receive free
curative care. Further research will be needed regarding the
experience of distributing IPTc at scale outside a trial setting and
the evolution of perceptions over time, especially if high
community-level coverage of IPTc over several years were to
decrease not only the incidence of malaria but also the perceived
threat of malaria.
Conclusion
This study of perceptions of IPTc within the context of trials
conducted in Burkina Faso and Mali provides promising
indications of the potential to deliver IPTc effectively at scale.
IPTc was compatible with local experiences and perceptions of
childhood illness and there was no evidence that IPTc was
perceived as a substitute for bed net usage, nor that it would
inhibit care seeking. Trust in and respect for health and other
authorities emerged as an important motivator for participation.
The use of single-dose formulations could increase the speed and
success of IPTc implementation at scale, as would integration and
joint marketing of IPTc as part of a package of activities, such as
LLIN distribution and free curative care, for which demand is
already high.
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